Example: Heart Attack

Search clinical trials for: Cytarabine

Total 1352 results

NCT04121819

Recruiting

AraC for Newly Diagnosed Adult Langerhans Cell Histiocytosis

Conditions: Langerhans Cell Histiocytosis
NCT02926586

Unknown status

Fludarabine and Cytarabine Versus High-dose Cytarabine for CBF-AML

Conditions: Acute Myeloid Leukemia; Core-Binding Factor
NCT02930109

Recruiting

A Study of PTX-200 (Triciribine) Plus Cytarabine in Refractory or Relapsed Acute Leukemia

Conditions: Acute Leukemia
NCT03021330

Recruiting

Efficacy of Intermediate-Dose Cytarabine Induction Regimen in Adult AML

Conditions: AML
NCT02840539

Recruiting

Trial of Bortezomib, Cytarabine, and Dexamethasone in Mantle Cell Lymphoma

Conditions: Mantle Cell Lymphoma
NCT02670707

Recruiting

Vinblastine/Prednisone Versus Single Therapy With Cytarabine for Langerhans Cell Histiocytosis (LCH)

Conditions: Langerhans Cell Histiocytosis
NCT01191541

Unknown status

Cytarabine (Ara-C) in Children With Acute Promyelocytic Leukemia (APL)

Conditions: Leukemia
NCT00334074

Completed

Clofarabine and Ara-C for the Treatment of Relapsed AML and Untreated MDS

Conditions: Acute Myelogenous Leukemia; Myelodysplastic Syndromes; Chronic Myelogenous Leukemia
NCT00541866

Completed

Safety and Tolerability Study of Voreloxin and Cytarabine Combination in Acute Myeloid Leukemia in Humans

Conditions: Acute Myeloid Leukemia
NCT01191801

Completed

Study of Vosaroxin or Placebo in Combination With Cytarabine in Patients With First Relapsed or Refractory AML

Conditions: Acute Myeloid Leukemia
NCT01960387

Terminated

Phase II Clofarabine and Cytarabine for Newly Diagnosed Acute Myeloid Leukemia

Conditions: Acute Myeloid Leukemia
NCT02875093

Terminated

Ph 1 Study of ADI-PEG 20 Plus Low Dose Cytarabine in Older Patients With AML

Conditions: Acute Myeloid Leukemia
NCT02024308

Unknown status

AML1-ETO Acute Myeloid Leukemia With Fludarabine and Cytarabine Chemotherapy

Conditions: Acute Myeloid Leukemia; AML1-ETO Fusion Protein Expression
NCT02957032

Unknown status

A Study of the Tumor-targeting Human F16IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Very Low-dose Cytarabine in Patients With AML Relapse After Allogeneic Hematopoietic Stem Cell Transplantation

Conditions: Acute Myeloid Leukemia, Relapsed, Adult
NCT03016988

Unknown status

The Efficacy and Safety of Bortezomib Combined With Fludarabine and Cytarabine Treatment for Mantle Cell Lymphoma

Conditions: Mantle Cell Lymphoma
NCT00513305

Terminated

Cytarabine in Combination With Arsenic Trioxide vs. Cytarabine Alone in Elderly Patients With Acute Myeloid Leukemia

Conditions: Acute Myeloid Leukemia
NCT00583102

Terminated

Dose Escalation Phase I/II Study of Lovastatin With High-Dose Cytarabine for Refractory or Relapsed AML

Conditions: Acute Myeloid Leukemia
NCT02652871

Completed

LY2510924, Idarubicin and Cytarabine in Patients With Relapsed or Refractory Acute Myeloid Leukemia

Conditions: Leukemia
NCT02109627

Terminated

Ficlatuzumab With High Dose Cytarabine in Relapsed and Refractory AML

Conditions: Acute Myeloid Leukemia; Relapsed Acute Myeloid Leukemia; Refractory Acute Myeloid Leukemia
NCT01272245

Completed

Omacetaxine and Low Dose Cytarabine in Older Patients With Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)

Conditions: Leukemia
NCT01444742

Completed

Clofarabine Plus Low-Dose Cytarabine for Patients With Higher-Risk Myelodysplastic Syndrome (MDS)

Conditions: Leukemia; Myeloproliferative Diseases
NCT00480090

Completed

A Phase II Study of Ara-C (Cytarabine) in Men With Androgen Independent Prostate Cancer

Conditions: Prostate Cancer
NCT00422591

Completed

Standard Idarubicin and Cytarabine for the Treatment of Acute Myeloid Leukemia (AML)

Conditions: Leukemia; Acute Myeloid Leukemia; AML
NCT02658487

Active, not recruiting

Vosaroxin and Infusional Cytarabine in Treating Patients With Untreated Acute Myeloid Leukemia

Conditions: Acute Myeloid Leukemia; Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome; Acute Myeloid Leukemia With Multilineage Dysplasia; Myeloid Sarcoma; Secondary Acute Myeloid Leukemia; Therapy-Related Acute Myeloid Leukemia; Therapy-Related Myelodysplastic Syndrome
NCT00516828

Completed

Sorafenib and Low Dose Cytarabine in Older Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Conditions: Leukemia; Myelodysplastic Syndromes